In patients with HNSCC, CDKN2A alterations include homozygous deletions in approximately 30%, additional gene mutations in 10–20%, and epigenetic silencing in up to 80% of cases. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.